Because the medicine is still in clinical development, the safety picture comes from controlled trials
These include: Nausea (affecting up to 43% of patients at weight management doses) [3] [4] Vomiting (up to 23%) Diarrhoea (up to 30%) Constipation (up to 24%) Abdominal pain or discomfort These effects typically diminish over time as the body adapts, though some patients experience persistent symptoms requiring dose adjustment or discontinuation
Archived from the original on 6 June 2021
Their primary roles vary from making energy from the food we eat by releasing carbohydrates and breaking down amino acids, to creating red blood cells, and transporting oxygen and nutrients around the body in the blood
IMCIVREE is now the first and only FDA-approved therapy for acquired HO, offering a targeted approach that addresses the underlying biology of this disease and meets a critical unmet need for patients who previously had no treatment options, stated David Meeker, MD, chairman, chief executive officer, and president of Rhythm Pharmaceuticals